Feiba VH Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited effectiveness of factor replacement in inhibitor patients, increasing diagnosis of hemophilia with inhibitors, long clinical usage of bypassing agents, hospital reliance on plasma derived therapies, improved survival of hemophilia patients.

The growth in the forecast period can be attributed to growth in personalized hemophilia management, expanding access to specialty hemophilia centers, rising awareness of inhibitor testing, improved treatment adherence, healthcare infrastructure development. Major trends in the forecast period include rising use of bypassing agents, growth in inhibitor positive hemophilia cases, preference for rapid bleeding control therapies, expansion of home based hemophilia care, improved emergency bleeding management.

The rising prevalence of hemophilia is expected to drive the expansion of the feiba VH market in the coming years. Hemophilia is a genetic disorder that impairs the blood's clotting ability, resulting in excessive bleeding. This increase in prevalence is linked to factors such as improved diagnosis, advancements in genetic testing, and better access to healthcare. FEIBA VH works by bypassing the disrupted or deficient clotting pathway, allowing blood to clot even in the presence of inhibitors. This mechanism helps manage and prevent spontaneous bleeding, ensuring proper hemostasis for hemophilia patients. For example, in April 2025, Pfizer Inc., a US-based pharmaceutical and biotechnology company, reported that during the 2023/24 period, the UK hemophilia A and B patient population exceeded 11,800 individuals, highlighting a significant and clinically relevant treated population. Therefore, the rising prevalence of hemophilia is fueling the growth of the feiba VH market.

Increasing healthcare expenditure is expected to further support the growth of the feiba VH market. Rising healthcare spending is driven by growing demand for advanced treatments, aging populations, and the increasing prevalence of chronic diseases worldwide. As expenditure rises, hospitals are more likely to invest in advanced therapies like FEIBA VH, enhancing patient care. Additionally, wider insurance coverage and reimbursement options make these therapies accessible to a larger population. For instance, in November 2023, the Canadian Institute for Health Information reported that total health spending in Canada was projected to reach $344 billion in 2023, equating to $8,740 per person. This represents a 2.8% increase from the previous year, which saw only a 1.5% growth in 2022, indicating a significant rebound in healthcare investment. Thus, rising healthcare expenditure is driving the feiba VH market forward.

The growing number of surgeries is also expected to boost the feiba VH market. Surgeries involve manual or invasive procedures to treat or diagnose conditions, often by cutting, removing, or repairing tissues. Surgical procedures are increasing due to factors such as an aging population, advances in medical technology, rising chronic disease prevalence, and improved healthcare access. FEIBA VH is used in surgeries for hemophilia A or B patients with inhibitors to standard clotting factors, helping bypass these inhibitors and support proper blood clotting. This reduces bleeding risks and allows for safer surgical procedures. For example, in May 2025, the Australian Institute of Health and Welfare reported that public hospitals admitted 778,500 elective surgery patients in 2023-24, marking a 5.8% year-on-year increase compared with 2022-23. Therefore, the increasing number of surgeries is expected to drive the growth of the feiba VH market.

Major companies operating in the feiba vh market are Takeda Pharmaceuticals U.S.A. Inc.

North America was the largest region in the feiba VH market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the feiba vh market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the feiba vh market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the feiba vh market by increasing costs associated with plasma collection, fractionation equipment, and international transportation of plasma derived products. These effects are most significant in hospital and specialty pharmacy segments across north america and europe where import dependency is high. Higher tariffs can contribute to pricing pressure and procurement challenges for hemophilia care centers. At the same time, tariffs are encouraging domestic plasma processing investments and strengthening regional self sufficiency in critical coagulation therapies.

The feiba vh market research report is one of a series of new reports that provides feiba vh market statistics, including feiba vh industry global market size, regional shares, competitors with a feiba vh market share, detailed feiba vh market segments, market trends and opportunities, and any further data you may need to thrive in the feiba vh industry. This feiba vh market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Feiba VH, also called anti-inhibitor coagulant complex, is a medication used to manage bleeding in individuals with hemophilia who have developed inhibitors (antibodies) that make standard clotting factor treatments ineffective. By bypassing the impaired clotting pathway, Feiba VH helps blood to clot and control bleeding. It is especially effective in treating bleeding episodes and supporting the overall health of people with hemophilia and inhibitors.

The primary clinical indications for Feiba VH include hemophilia A with inhibitors, hemophilia B with inhibitors, and acquired hemophilia. Hemophilia A with inhibitors occurs when antibodies reduce the effectiveness of factor VIII treatment, complicating bleeding control and necessitating specialized therapies like Feiba VH. The medication is distributed through multiple channels, including hospitals, specialty pharmacies, and direct-to-consumer, and is used by various end users, including both adults and pediatric patients.

The feiba VH market consists of sales of feiba VH vials, feiba VH lyophilized powder, and feiba VH intravenous infusion solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.